Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scale

Published on January 7, 2025

human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative

Continue reading on website
Other news

Fazeshift secures $4MM Seed Round Led by Gradient to Automate Accounts Receivable with AI

January 7, 2025
seed funding led by Gradient , Google's early-stage AI fund. The round also included investment from Y Combinator, Wayfinder, Pioneer Fund,

Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million

January 7, 2025
our anticipated future operating and financial expectations and opportunities, customer opportunities and relationships are forward-looking